Physician profile
Mark E Silver
NPI 1639178114
$3,143.36
in general payments reported to CMS, 2019-2025
32 companies · $163 in 2025
The $163 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $653 · 2020: $575 · 2021: $680 · 2022: $485 · 2023: $294 · 2024: $294 · 2025: $163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $734 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $733.94 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $403.56 | 2021-2023 | Vraylar |
| Janssen Pharmaceuticals, INC | $377.48 | 2019-2023 | Xarelto |
| Glaxosmithkline, LLC. | $292.17 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $282.93 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $239.43 | 2019-2025 | Breztri |
| Otsuka America Pharmaceutical, INC. | $223.01 | 2019-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $212.98 | 2019-2023 | Eliquis |
| Novartis Pharmaceuticals Corporation | $138.45 | 2019-2025 | |
| Astellas Pharma US INC | $137.16 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $131.21 | 2019-2020 | |
| Novo Nordisk INC | $56.53 | 2020-2025 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.24 | 2019-2025 | Jardiance |
| Allergan, INC. | $55.00 | 2020 | |
| Sanofi Pasteur INC. | $46.70 | 2022-2023 | |
| Dexcom, INC. | $44.82 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $41.50 | 2021 | |
| Sanofi-Aventis U.S. LLC | $40.61 | 2021 | |
| Amarin Pharma, INC. | $39.52 | 2020 | |
| Lundbeck LLC | $36.87 | 2023 | Rexulti |
| Smith+Nephew, INC. | $34.63 | 2020 | |
| Exact Sciences Corporation | $33.68 | 2024 | Cologuard Collection Kit |
| Pfizer INC. | $29.75 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.29 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.53 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.67 | 2022 | |
| Amgen INC. | $21.90 | 2025 | Repatha, Otezla |
| Viatris Specialty LLC | $21.19 | 2025 | Yupelri |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.00 | 2024 | Lifevest |
| Mylan Specialty L.P. | $15.53 | 2020 | |
| Alkermes, INC. | $15.51 | 2024 | Aristada, Lybalvi |
| Organon LLC | $14.25 | 2024 | |
| Biodelivery Sciences International, INC. | $11.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Silver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.